Market Place
Sourcing Support
Microbion Reports Positive Phase 2 Data for Diabetic Foot Ulcers
13 Nov 2024 //
PR NEWSWIRE
Microbion Receives Award at Advanced Wound Care Summit USA`s Innovation Showcase
25 Apr 2024 //
PR NEWSWIRE
Microbion Selected For Advanced Wound Care Summit USA
15 Apr 2024 //
PR NEWSWIRE
Microbion Pravibismane Ph 1b DFU Published in International Wound Journal
04 Apr 2024 //
PR NEWSWIRE
Microbion`s Pravibismane Granted Second FDA Orphan Drug Designation
30 Jan 2024 //
PR NEWSWIRE
Microbion CEO to Participate in Panel Discussion at BioFuture 2023
05 Oct 2023 //
PR NEWSWIRE
Microbion Presented Pravibismane Data Against Mycobacteroides abscessus
15 Aug 2023 //
PR NEWSWIRE
Microbion to Present Design of Phase 2 Treating Diabetic Foot Ulcer Infections
14 Aug 2023 //
PR NEWSWIRE
Microbion Granted US Patent for Use of Inhaled Pravibismane
04 Apr 2023 //
PR NEWSWIRE
Microbion Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane
09 Mar 2023 //
PR NEWSWIRE
Microbion Highlights Pravibismane Activity Against Cystic Fibrosis
03 Nov 2022 //
PRNEWSWIRE
Microbion to present Data for Pravibismane`s Effect on Bacterial Energetics
11 Oct 2022 //
PRNEWSWIRE
Microbion Announces Granting of US Patent for Pharma Composition of Pravibismane
04 Oct 2022 //
PRNEWSWIRE
Microbion Corporation Receives up to $2.1M in Funding
07 Jun 2022 //
PRNEWSWIRE
Microbion Corp Announces Data Highlighting In Vitro Activity of Pravibismane
01 Jun 2022 //
PRNEWSWIRE
Microbion Robert A. Gillam as Chairman of Microbion`s Board of Directors
29 Jul 2021 //
PRNEWSWIRE
Microbion Corporation Receives Additional Funding Support the Cystic Fibrosis
22 Feb 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.